1. 2362 Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients. (September 2015) Authors: Vivaldi, C.; Vasile, E.; Fornaro, L.; Caparello, C.; Musettini, G.; Pasquini, G.; Lencioni, M.; Ricci, S.; Falcone, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2372 Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer?. (September 2015) Authors: Musettini, G.; Caparello, C.; Pasquini, G.; Vivaldi, C.; Lencioni, M.; Petrini, I.; Fabrini, M.G.; Pallabazzer, G.; D'Imporzano, S.; Solito, B.; Santi, S.; Fornaro, L.; Vasile, E.; Falcone, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S460 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Circulating micrornas as dynamic biomarkers of disease progression during folfirinox therapy in unresectable pancreatic ductal adenocarcinoma (pdac). (April 2016) Authors: Meijer, L.L.; Garajová, I.; Caparello, C.; Le Large, T.Y.S.; Funel, N.; Vasile, E.; Giovannetti, E.; Zonderhuis, B.M.; Daams, F.; Kazemier, G. Journal: HPB Issue: Volume 18(2016)Supplement 1 Page Start: e43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX in advanced pancreatic ductal adenocarcinoma. (2019) Authors: Meijer, L.; Garajová, I.; Caparello, C.; Le Large, T.; Funel, N.; Vasile, E.; Zonderhuis, B.; Daams, F.; Giovannetti, E.; Kazemier, G. Journal: HPB Issue: Volume 21(2019)Supplement 3 Page Start: S760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P-147Outcome of second-line chemotherapy (CT2) after first-line CT (CT1) with platinum plus gemcitabine in advanced biliary tract cancer (aBTC): is it worthwhile?. (24th June 2015) Authors: Fornaro, L.; Vivaldi, C.; Brandi, G.; Cereda, S.; Aprile, G.; Santini, D.; Silvestris, N.; Lonardi, S.; Leone, F.; Milella, M.; Caparello, C.; Musettini, G.; Pasquini, G.; Vasile, E. Journal: Annals of oncology Issue: Volume 26(2015)Supplement 4 Page Start: iv42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗